Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy

Chinese Academy of Medical Sciences1 site in 1 country40 target enrollmentOctober 2010

ConditionsRectal Cancer

Overview

Phase: N/A
Intervention: Not specified
Conditions: Rectal Cancer
Sponsor: Chinese Academy of Medical Sciences
Enrollment: 40
Locations: 1
Primary Endpoint: Endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to determine the role of endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values in predicting the tumor regression after concurrent chemoradiotherapy for rectal cancer.

Detailed Description

We use endoscopic ultrasound to measure the primary tumor maximum diameter changes to predict the tumor regression after concurrent chemoradiotherapy for rectal cancer

Registry

clinicaltrials.gov

Start Date

October 2010

End Date

December 2015

Last Updated

12 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Chinese Academy of Medical Sciences

Responsible Party

Principal Investigator

Jing Jin, M.D.

Director of Abdomen Division, Radiation Oncology Department

Chinese Academy of Medical Sciences

Eligibility Criteria

Inclusion Criteria

•pathologically confirmed rectal cancer, preoperative stage II / III (T3-4N0 or T1-4N + M0).
•tumor distance from anus less than 12 cm.
•KPS score not less than 70
•can be tolerated chemotherapy and radiotherapy.
•pelvic who had no history of radiation therapy.
•Non-allergic history of fluorouracil or platinum-based chemotherapy drugs.
•a full understanding of the study, the ability to complete all of the treatment plan, follow up the conditions and sign the informed consent.

Exclusion Criteria

•other malignancy (past or at the same time), does not include curable non-melanoma skin cancer and cervical carcinoma in situ; does not include resectable primary colon cancer (synchronous or metachronous).
•pregnant or lactating patients.
•fertility but did not use contraceptive measures.
•existing active infection.
•merge serious complications, can not tolerate the treatment, such as 6 months of myocardial infarction, mental illness, uncontrollable diabetes or uncontrollable hypertension or hypotension.
•concurrent treatment with other anticancer drugs.
•can not complete treatment or follow-up.